| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036609389 |
| P356 | DOI | 10.1007/S10911-012-9268-Y |
| P953 | full work available at URL | http://link.springer.com/article/10.1007/s10911-012-9268-y/fulltext.html |
| http://link.springer.com/content/pdf/10.1007/s10911-012-9268-y | ||
| http://link.springer.com/content/pdf/10.1007/s10911-012-9268-y.pdf | ||
| https://doi.org/10.1007/s10911-012-9268-y | ||
| https://europepmc.org/articles/PMC3534944 | ||
| https://europepmc.org/articles/pmc3534944?pdf=render | ||
| https://europepmc.org/articles/PMC3534944?pdf=render | ||
| P3181 | OpenCitations bibliographic resource ID | 2740499 |
| P932 | PMC publication ID | 3534944 |
| P698 | PubMed publication ID | 23054135 |
| P5875 | ResearchGate publication ID | 232230781 |
| P50 | author | Douglas Yee | Q56985470 |
| P2093 | author name string | Yuzhe Yang | |
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Humanization of an anti-p185HER2 antibody for human cancer therapy | Q24561842 | ||
| Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans | Q24618226 | ||
| Unraveling insulin-like growth factor binding protein-3 actions in human disease | Q24650060 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas | Q27851824 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance | Q28141690 | ||
| A prospective study of plasma C-peptide and colorectal cancer risk in men | Q28168133 | ||
| I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 | ||
| Molecular mechanisms of erbB2-mediated breast cancer chemoresistance | Q28256822 | ||
| A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. | Q54570192 | ||
| Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expressionin Vitroandin Vivo | Q62267728 | ||
| Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells | Q62267733 | ||
| Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells | Q72524963 | ||
| A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I | Q73274526 | ||
| Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R | Q74428783 | ||
| Tamoxifen in the treatment of breast cancer | Q77598704 | ||
| Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy | Q79750183 | ||
| Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo | Q79929885 | ||
| Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors | Q80200141 | ||
| Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect | Q53948454 | ||
| The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins | Q28507365 | ||
| Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta | Q28587815 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Insulin and insulin-like growth factor signalling in neoplasia | Q29619495 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells | Q30433113 | ||
| A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. | Q33196244 | ||
| Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics | Q33330850 | ||
| Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
| The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. | Q33745823 | ||
| Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. | Q33858986 | ||
| Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. | Q33927952 | ||
| Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. | Q33974134 | ||
| The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma | Q34001234 | ||
| Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model | Q34123598 | ||
| Elevated insulin receptor content in human breast cancer | Q34263132 | ||
| Risk factors for breast cancer and expression of insulin-like growth factor-2 (IGF-2) in women with breast cancer in Wuhan City, China | Q34290897 | ||
| Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab | Q34577559 | ||
| Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice | Q34578428 | ||
| The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells | Q34609956 | ||
| High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy | Q34774874 | ||
| Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. | Q35002762 | ||
| Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells | Q35079017 | ||
| Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells | Q35147146 | ||
| IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors | Q35836632 | ||
| Disproportionate growth in mice with Igf-2 transgenes | Q35850859 | ||
| Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment | Q35903979 | ||
| Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor | Q35910960 | ||
| The IGF-I/IGF-I receptor pathway: Implications in the Pathophysiology of Thyroid Cancer | Q36320960 | ||
| Targeting insulin-like growth factor pathways. | Q36383365 | ||
| Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes | Q36393112 | ||
| Disrupting insulin-like growth factor signaling as a potential cancer therapy | Q36712708 | ||
| Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation | Q36716270 | ||
| Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer | Q36981862 | ||
| Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women | Q37090766 | ||
| Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo | Q37287624 | ||
| Regulation of breast cancer metastasis by IGF signaling | Q37334032 | ||
| Knocking down barriers: advances in siRNA delivery | Q37380671 | ||
| Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth | Q37607183 | ||
| Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer | Q37731144 | ||
| Insulin receptor and cancer. | Q37878709 | ||
| The insulin and insulin-like growth factor receptor family in neoplasia: an update | Q37984217 | ||
| A novel role for insulin resistance in the connection between obesity and postmenopausal breast cancer | Q39344660 | ||
| Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro | Q39346958 | ||
| MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor | Q39349521 | ||
| Metformin reduces endogenous reactive oxygen species and associated DNA damage | Q39409229 | ||
| Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion | Q39460470 | ||
| MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor | Q39495719 | ||
| Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens | Q39560529 | ||
| Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth | Q39606299 | ||
| Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells | Q39677802 | ||
| BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. | Q39765527 | ||
| Reversibility and recurrence of IGF-IR-induced mammary tumors | Q39859193 | ||
| Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. | Q39877535 | ||
| The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors | Q39899686 | ||
| Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models | Q39978832 | ||
| Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. | Q40219858 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. | Q40361501 | ||
| Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor | Q40427703 | ||
| Determinants of rapamycin sensitivity in breast cancer cells | Q40590648 | ||
| A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. | Q40607057 | ||
| A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. | Q40616617 | ||
| Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines | Q40769212 | ||
| AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. | Q40824440 | ||
| Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines | Q41481089 | ||
| Estradiol Down-Regulates the Mannose-6-Phosphate/Insulin-Like Growth Factor-II Receptor Gene and Induces Cathepsin-D in Breast Cancer Cells: A Receptor Saturation Mechanism to Increase the Secretion of Lysosomal Proenzymes | Q41682889 | ||
| Targeting IGF-1R: at a crossroad | Q41956658 | ||
| Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor | Q42493841 | ||
| Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells | Q42513860 | ||
| mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer | Q42660087 | ||
| Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail | Q42738098 | ||
| In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase | Q42799629 | ||
| Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase | Q43130305 | ||
| Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study | Q43503861 | ||
| Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. | Q43823975 | ||
| Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer | Q43937165 | ||
| Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. | Q44246942 | ||
| Insulin receptor expression and clinical outcome in node-negative breast cancer | Q44857623 | ||
| Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors | Q46972238 | ||
| Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors | Q47860361 | ||
| Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism | Q51803667 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| P433 | issue | 3-4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| targeted therapy | Q492646 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 251-61 | |
| P577 | publication date | 2012-10-10 | |
| 2012-12-01 | |||
| P1433 | published in | Journal of Mammary Gland Biology and Neoplasia | Q15724460 |
| P1476 | title | Targeting insulin and insulin-like growth factor signaling in breast cancer | |
| Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer | |||
| P478 | volume | 17 |
| Q36136323 | Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells. |
| Q28109681 | Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer |
| Q47677316 | CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression |
| Q38162118 | Clinical studies examining the impact of obesity on breast cancer risk and prognosis |
| Q90699218 | Comprehensive review of targeted therapy for colorectal cancer |
| Q26860821 | Crosstalk of the Insulin-Like Growth Factor Receptor with the Wnt Signaling Pathway in Breast Cancer |
| Q38824693 | Does soy protein affect circulating levels of unbound IGF-1? |
| Q43128718 | Effect of hypoxia on hypoxia inducible factor-1α, insulin-like growth factor I and vascular endothelial growth factor expression in hepatocellular carcinoma HepG2 cells |
| Q34434910 | Elevated GH/IGF-I promotes mammary tumors in high-fat, but not low-fat, fed mice |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q26741242 | Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature |
| Q37607405 | G(i)α proteins exhibit functional differences in the activation of ERK1/2, Akt and mTORC1 by growth factors in normal and breast cancer cells |
| Q36265430 | Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma |
| Q35185029 | Highly specific role of the insulin receptor in breast cancer progression |
| Q36083412 | IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation |
| Q33551399 | IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. |
| Q53171362 | IGF-I stimulates ERβ and aromatase expression via IGF1R/PI3K/AKT-mediated transcriptional activation in endometriosis |
| Q33953601 | Identification of collaborative driver pathways in breast cancer |
| Q38953223 | Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma. |
| Q62267699 | Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells |
| Q39136080 | Insulin induces C2C12 cell proliferation and apoptosis through regulation of cyclin D1 and BAD expression |
| Q39097888 | Insulin induces proliferation and cardiac differentiation of P19CL6 cells in a dose-dependent manner |
| Q101216968 | Insulin receptor substrate-1 (IRS-1) mediates progesterone receptor-driven stemness and endocrine resistance in oestrogen receptor+ breast cancer |
| Q26800001 | Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease |
| Q47117809 | Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer. |
| Q59336737 | Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment |
| Q35000609 | Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial |
| Q58597858 | Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk |
| Q36759471 | Lactation opposes pappalysin-1-driven pregnancy-associated breast cancer. |
| Q37200502 | Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients |
| Q35535296 | Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation |
| Q37559035 | Role of carbohydrate response element-binding protein (ChREBP) in generating an aerobic metabolic phenotype and in breast cancer progression |
| Q34774884 | Standard of care and promising new agents for triple negative metastatic breast cancer |
| Q50890602 | Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds. |
| Q37427949 | The Impact of Diabetes on the Risk of Prostate Cancer Development according to Body Mass Index: A 10-year Nationwide Cohort Study |
| Q37551261 | The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells |
| Q30244095 | The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies |
| Q35917441 | Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST. |
Search more.